Urinary dysfunction improver
By using 2-oxaphane compounds with hydroxyl groups or oxo groups on the steroid backbone as urinary disorder improvement agents, the safety and therapeutic effect of urinary disorder improvement agents in the prior art are solved. Problem, high safety and high therapeutic effect are achieved, and the effect of improving urination disorders is not related to prostate hypertrophy.
Patent Information
- Application Number
- CN202080069198.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-01-29
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-01-29
AI Technical Summary
Existing urinary disorder improvement agents lack high therapeutic effect and high safety when administered for a long time, and their therapeutic effect is not related to the degree of prostate hypertrophy and cannot effectively improve urinary disorders.
Using 2-oxaphane compounds with high anti-androgenic activity, compounds with hydroxyl or oxo groups present at predetermined sites of the steroid backbone are used as urinary disorder improvement agents for the treatment or relief of urinary disorders, regardless of the presence of prostate or not Hypertrophy all showed high therapeutic effects.
This compound or its pharmaceutically acceptable salt can effectively treat or improve urination disorders, is highly safe, maintains high therapeutic effect even if long-term administration is given, and is irrelevant to the degree of prostate hypertrophy. It is suitable for patients without benign prostate hyperplasia. .
Smart Images

Figure CN114502239B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a useful urination disorder improving agent containing a pregnane compound or a pharmaceutically acceptable salt thereof as an active ingredient and for improving urination disorder such as residual urine feeling. Background Art
[0002] With the development of an aging society, it is expected to improve or alleviate (or reduce) the urination disorder of the elderly, wherein the urination disorder includes diseases or symptoms such as dysuria, residual urine feeling, frequent urination, and urinary incontinence. As a medicament for improving this urination disorder, Japanese patent application No. H5-155773 (JP H5-155773 A, Patent Document 1) discloses xanthine derivatives that are effective in treating and preventing urination disorders (such as frequent urination or urinary incontinence). Japanese patent application No. H8-3045 (JP H8-3045 A, Patent Document 2) discloses urination disorder improvement drugs containing N-substituted indole derivatives as active ingredients. WO2012 / 020749 (Patent Document 3) discloses triazine derivatives and pharmaceutical compositions containing the triazine derivatives and having analgesic effects or urination disorder improvement effects.
[0003] Commercially available drugs for improving urination disorders include, for example, α1 blockers and 5α-reductase inhibitors, etc. 5α-reductase inhibitors prevent the production of dihydrotestosterone from testosterone, shrink the enlarged prostate, and improve urination disorders.
[0004] Japanese Patent Application Early Publication No. S61-204198 (JP S61-204198 A, Patent Document 4) and Endocrine Journal 1994, 41 (4), 445-452 (Non-Patent Document 1) disclose TZP-4238 (17α-acetoxy-6-chloro-2-oxa-4,6-pregnene-3,20-dione) as an antiandrogen agent, and also disclose that TZP-4238 is useful in treating diseases such as prostatic hypertrophy (or prostate enlargement) and prostate cancer.
[0005] Japanese Patent No. 2591640 (JP 2591640 B, Patent Document 5) discloses 2-oxapregnanol compounds as compounds having anti-androgen activity, including 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione. The document discloses that the compounds are used as agents for treating androgen-dependent diseases such as prostatic hypertrophy, prostate cancer, and alopecia.
[0006] Regarding plant preparations, Japanese Patent Application Early Publication No. 2011-20972 (JP 2011-20972A, Patent Document 6) discloses a urination disorder improver containing a saw palmetto extract and oleic acid and myristic acid in a ratio of 1:0 to 2:3. Patent Document 6 discloses that as men age, prostate hypertrophy causes the part near the urethra (periurethral glands) to proliferate and become larger (mechanical obstruction), and dihydrotestosterone accumulates in the prostate, causing the development of benign prostatic hyperplasia (BPH). The document discloses that the symptoms of benign prostatic hyperplasia include lower urinary tract symptoms, such as dysuria and frequent urination.
[0007] However, prostatic hypertrophy does not necessarily lead to urinary dysfunction. For example, World Journal of Urology, 13, 9-13 (1995) (Non-Patent Document 2) reported a statistically significant relationship between prostate size and bladder outlet obstruction, but there was no correlation between urinary dysfunction symptoms and the degree of bladder outlet obstruction or prostate size.
[0008] The Journal of Urology, 150, 351-358, August, 1993 (non-patent literature 3) reported that there is no correlation between the size of prostate and residual urine volume, and there is no correlation between residual urine volume, the size of prostate and various symptoms. Especially, the document provides the correlation model of the patient with benign prostatic hyperplasia (BPH), and discloses that although the sample size is relatively large, there is no statistically significant relationship between the severity of symptoms and residual urine volume, the size of prostate or prostate-specific antigen (PSA) level, and the document discloses that prostatic hypertrophy is also a feature of BPH, but is not a key factor for producing symptoms or physiological outlet obstruction. In addition, the document discloses that in some patients (individuals), even if the hyperplasia degree of the periurethral area is small, physiological disorders may still be induced, and in other patients (individuals), considerable hyperplasia may occur without developing into obstacles.
[0009] Therefore, it is expected to effectively treat or improve urination disorders regardless of the degree or presence of prostatic hypertrophy. Further, the treatment of urination disorders involves long-term administration to patients such as the elderly, and should have high therapeutic efficacy and high safety.
[0010] List of References
[0011] Patent Literature
[0012] Patent Document 1: JP H5-155773 A (claims)
[0013] Patent Document 2: JP H8-3045 A (claims)
[0014] Patent Document 3: WO 2012 / 020749 (claims)
[0015] Patent Document 4: JP S61-204198 A (claims, and page 1, right column)
[0016] Patent Document 5: JP 2591640 B (claims, and column 11, line 49 to column 12, line 49)
[0017] Patent Document 6: JP 2011-20972 A (claims and
[0002] )
[0018] Non-patent literature
[0019] Non-patent literature 1: Endocrine Journal 1994, 41(4), 445-452
[0020] Non-patent document 2: World Journal of Urology, 13, 9-13 (1995) (Overview)
[0021] Non-patent document 3: The Journal of Urology, 150, 351-358 August 1993 (page 354, right column, lines 5 to 10, page 355, left column, line 9 from the bottom to line 6 of the right column of page 355, Tables 3 and 5) SUMMARY OF THE INVENTION
[0023] Technical issues
[0024] Therefore, an object of the present invention is to provide a urination disorder improving agent for treating or improving (or alleviating or alleviating) urination disorder.
[0025] Another object of the present invention is to provide a urination disorder improving agent which has high safety and can be used to treat or improve urination disorder with a high therapeutic or improving effect even when the agent is administered for a long period of time.
[0026] Still another object of the present invention is to provide a urination disorder improving agent for treating or alleviating (or alleviating) urination disorder which is not related to the degree or existence of prostatic hypertrophy (or prostate enlargement).
[0027] Ways to solve the problem
[0028] In order to achieve the above-mentioned purpose, the inventors of the present invention have conducted in-depth research on the relationship between urinary disorders and 2-oxapregnanol compounds having an oxo group at the 2-position of the steroid skeleton and having high anti-androgenic activity, and found that even 2-oxapregnanol compounds having high anti-androgenic activity have great differences in the improvement of urinary disorders depending on the presence or absence of a hydroxyl group or an oxo group at a predetermined position of the steroid skeleton. In particular, the inventors found that compounds without a hydroxyl group at a predetermined position of the steroid skeleton, regardless of whether they have high anti-androgenic activity, show no therapeutic effect on urinary disorders in subjects without prostatic hypertrophy, but compounds with a hydroxyl group or an oxo group at a predetermined position of the steroid skeleton show high therapeutic or improving effects on urinary disorders regardless of whether prostatic hypertrophy exists. The present invention was completed based on the above-mentioned findings.
[0029] That is, the present invention provides a urination disorder improving agent (urination disorder alleviating agent, or an agent for improving or alleviating urination disorder) containing a 2-oxapregnanolone compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. Incidentally, in the following formula (1), each position of the steroid skeleton is indicated by a position number.
[0030] [Chemical formula 1]
[0031]
[0032] In the formula, R1 to R3 are the same or different and each represents an alkyl group, R4 represents a hydrogen atom or an alkylcarbonyl group, X represents a halogen atom, and Y represents a hydroxyl group or an oxo group bonded to the 11-, 15- or 16-position of the steroid skeleton.
[0033] R1 to R3 are the same or different, and each may represent C 1-4 R4 can be a lower alkanoyl or acyl (C 1-4 The halogen atom represented by X may be a chlorine atom. Y may be a hydroxyl group or an oxo group bonded to the 15-position of the steroid skeleton. A representative 2-oxapregnanol compound represented by formula (1) may be 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione.
[0034] The compound or its pharmaceutically acceptable salt is used to prevent, treat or improve or alleviate (or alleviate) urination disorder or symptom. For example, urination disorder can be selected from residual urine feeling, weakened urine potential, hesitancy (or delayed urination), straining (or abdominal pressure urination), terminal dripping, urine dripping after urination, urinary incontinence (including urgency, abdominal pressure, mixed, overflow), frequent urination (including increased daytime frequency, nocturia and psychogenic frequent urination), urgency, bladder pain or bladder pain syndrome, pain during urination, bladder atrophy, neurogenic bladder, detrusor overactivity or overactive bladder (including primary, neurogenic, refractory), chronic cystitis, interstitial cystitis, chronic prostatitis, pelvic pain syndrome, underactive bladder, and at least one disease or symptom with impaired reflex contraction function detrusor overactivity (or, detrusor overactivity with impaired contraction). In particular, the compound or its pharmaceutically acceptable salt shows a high therapeutic or ameliorative effect on urination disorder, regardless of whether benign prostatic hyperplasia is present. That is, urination disorder can be any one of urination disorder without benign prostatic hyperplasia or urination disorder with benign prostatic hyperplasia. Therefore, the subject with urination disorder can be any one of male or female (male or female). In addition, urination disorder can also be urination disorder associated with smooth muscle contraction disorder. Urinary disorder can be urination disorder associated with at least one disease selected from the following: a disease causing or inducing neurogenic bladder; diabetes; and neuropathy associated with diabetes. Urinary disorder improvers can improve or promote urination. Therefore, urination disorder improvers can also be referred to as urination improvers or urination promoters.
[0035] The present invention includes a method for treating, improving or alleviating (or reducing) urination disorders (and a method for improving or promoting urination), the method comprising administering a 2-oxapregnanol compound represented by formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient to a subject suffering from urination disorders. In addition, the present invention includes the use of a 2-oxapregnanol compound represented by formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient for treating, improving or alleviating (or reducing) urination disorders (and improving or promoting urination); and the use of a 2-oxapregnanol compound represented by formula (1) or a pharmaceutically acceptable salt thereof for preparing a urination disorder improver, a urination improver or a urination promoter. The dosage for a human being as a subject (or patient) can be about 0.01 to 100 mg per day in terms of the compound represented by formula (1).
[0036] Advantageous Effects of the Invention
[0037] According to the present invention, the urination disorder improving agent comprises a specific 2-oxapregnanol compound or a pharmaceutically acceptable salt thereof, and thus can effectively treat or improve (or alleviate or reduce) urination disorder. In addition, the compound or a pharmaceutically acceptable salt thereof has high safety, and even if administered for a long time, it can improve urination disorder with a high therapeutic or improving effect. Further, the compound or a pharmaceutically acceptable salt thereof has a hydroxyl group or an oxo group at a predetermined position of the steroid skeleton, and thus can treat or alleviate (or reduce) urination disorder, regardless of the degree or existence of prostatic hypertrophy. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] [ Figure 1 ] Figure 1 : is a graph showing the relationship between the residual urine volume and the test substance under no anesthesia and under anesthesia in Test Example 1.
[0040] [ Figure 2 ] Figure 2 : is a graph showing the relationship between the urination efficiency and the test substance under no anesthesia and under anesthesia in Test Example 1.
[0041] [ Figure 3 ] Figure 3 is a graph showing the relationship between the bladder capacity and the test substance in Test Example 1.
[0042] [ Figure 4 ] Figure 4 is a graph showing the relationship between the bladder wet weight and the test substance in Test Example 1.
[0043] [ Figure 5 ] Figure 5 is a graph showing the relationship between the wet weight of kidney and the test substance in Test Example 1.
[0044] [ Figure 6 ] Figure 6 is a graph showing the relationship between the survival rate and the test substance in Test Example 1.
[0045] [ Figure 7 ] Figure 7 : is a graph showing the relationship between the residual urine volume and the test substance in Test Example 2.
[0046] [ Figure 8 ] Figure 8 : is a graph showing the relationship between urination efficiency and the test substance in Test Example 2.
[0047] [ Fig. 9 ] Fig. 9 : is a graph showing the relationship between the bladder contraction tension caused by rectangular wave electric field stimulation and the test substance in Test Example 3.
[0048] [ Fig.10 ] Fig.10The results show that carbachol (muscarinic receptor stimulation) and KCl (depolarization-dependent Ca 2+ A graph showing the relationship between bladder contraction tension (stimulation) and test substances.
[0049] [ Fig.11 ] Fig.11 This is a graph showing the relationship between the bladder capacity in cystometry (CMG) under awake conditions in Test Example 4 and the test substance.
[0050] [ Fig.12 ] Fig.12 Graph showing the relationship between the residual urine volume in cystometry (CMG) and the test substance under awake conditions in Test Example 4.
[0051] [ Fig.13 ] Fig.13 : is a graph showing the relationship between the urination efficiency in cystometry (CMG) under awake conditions and the test substance in Test Example 4.
[0052] [ Fig.14 ] Fig.14 It is a graph showing the relationship between the bladder capacity in cystometry (CMG) under anesthesia and the test substance in Test Example 4.
[0053] [ Fig.15 ] Fig.15 It is a graph showing the relationship between the residual urine volume in cystometry (CMG) under anesthesia and the test substance in Test Example 4.
[0054] [ Fig.16 ] Fig.16 It is a graph showing the relationship between the urination efficiency in cystometry (CMG) under anesthesia and the test substance in Test Example 4.
[0055] [ Fig.17 ] Fig.17 is a graph showing the results of nomogram analysis in Test Example 4.
[0056] [ Fig.18 ] Fig.18 is a graph showing the relationship between uterine weight and test substance in Test Example 5.
[0057] [ Fig.19 ] Fig.19 Graph showing the relationship between the residual urine volume in cystometry (CMG) and the test substance under awake conditions in Test Example 6.
[0058] [ Fig. 20 ] Fig. 20: is a graph showing the relationship between the urination efficiency in cystometry (CMG) under awake conditions and the test substance in Test Example 6.
[0059] [ Fig.21 ] Fig.21 is a graph showing the results of nomogram analysis in Test Example 6. Specific implementation plan
[0060] [2-Oxapregnane compound or a pharmaceutically acceptable salt thereof]
[0061] The compound represented by formula (1) is known as described in the above-mentioned Patent Document 5. As described above, such a compound has high anti-androgen activity and is used as a therapeutic agent for treating benign prostatic hyperplasia, but the compound has the property of being effective in treating or improving urination disorders not related to prostatic hypertrophy.
[0062] In the formula (1), as examples of the alkyl groups represented by R1 to R3, there may be mentioned linear or branched C 1-6 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl. Alkyl groups are usually straight-chain or branched C 1-4 Alkyl, preferably a straight chain or branched C 1-3 The alkyl group is more preferably a methyl group or an ethyl group, and the alkyl group is often a methyl group. In particular, R1 to R3 may be the same or different alkyl groups. R1 to R3 are often each a methyl group.
[0063] R4 can be any of a hydrogen atom or an alkylcarbonyl group, and is usually an alkylcarbonyl group (alkanoyl or acyl group). The alkylcarbonyl group (or acyl group) represented by R4 can include, for example, a straight chain or branched C 1-10 Alkyl-carbonyl, such as acetyl, propionyl, butyryl, isobutyryl, tert-butyryl, valeryl, hexanoyl. Alkylcarbonyl is usually a straight chain or branched C 1-6 Alkyl-carbonyl, preferably C 1-4 Alkyl-carbonyl, more preferably C 1-3 The alkyl-carbonyl group is often an acetyl group. It should be noted that the alkylcarbonyl group represented by R4 can be hydrolyzed and converted into a hydrogen atom by a hydrolase, and the hydrogen atom represented by R4 can be converted into an alkylcarbonyl group by an acyltransferase.
[0064] The halogen atom represented by X may include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom. The halogen atom is often a fluorine atom, a chlorine atom or a bromine atom, and particularly a chlorine atom.
[0065] The hydroxyl group or oxo group represented by Y may be located at any of the 11th, 15th, or 16th positions of the steroid skeleton. Generally, it is often bonded to the 15th position of the steroid skeleton.
[0066] The oxo group and hydroxyl group of the steroid skeleton can be mutually converted by the oxidoreductase in the body. Therefore, Y can be any one of the hydroxyl group or the oxo group. In many cases, Y is usually a hydroxyl group. In the case where Y is a hydroxyl group, the configuration of the hydroxyl group can be the α position or the β position represented by the following formula. For example, the configuration of the hydroxyl group bonded to the 15th position of the steroid skeleton can be the β position.
[0067] [Chemical formula 2]
[0068]
[0069] The compound represented by formula (1) may include 17α-C 1-4 Alkylcarbonyloxy-6-halogeno-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione, and 17α-C 1-4 Alkylcarbonyloxy-6-halo-2-oxa-4,6-pregnadiene-3,15,20-trione.
[0070] A preferred compound may have a hydroxyl group represented by Y at the 11-position, 15-position or 16-position of the steroid skeleton, and may be represented by the following formula (1a).
[0071] [Chemical formula 3]
[0072]
[0073] Representative examples of the compound represented by formula (1a) or a pharmaceutically acceptable salt thereof may include 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione or a pharmaceutically acceptable salt thereof.
[0074] The 2-oxapregnane compound represented by formula (1) or a pharmaceutically acceptable salt thereof may be a racemate, or may be an optically active substance (or an optical isomer). The 2-oxapregnane compound represented by formula (1) or a pharmaceutically acceptable salt thereof may be a metabolite.
[0075] Examples of salts may include salts of inorganic acids (e.g., hydrochloric acid or sulfuric acid), salts of organic acids (acetic acid), salts of inorganic bases (e.g., ammonia, alkali metals such as sodium or potassium, and alkaline earth metals such as calcium), salts of organic bases (e.g., amines such as triethylamine).
[0076] The 2-oxapregnane compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be produced according to a conventional method, for example, the method described in Patent Document 5.
[0077] The 2-oxapregnanolone represented by formula (1) or a pharmaceutically acceptable salt thereof may have anti-androgen activity or may function as an androgen receptor modulator. Furthermore, the compound may have both anti-androgen and anti-progesterone effects.
[0078] The urination disorder improving agent according to the present invention contains at least the 2-oxapregnanol compound represented by formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, and if necessary, may further contain other physiologically active ingredients or pharmacologically active ingredients (e.g., other urination improving agents). Examples of other urination improving agents (second urination improving agents) may include α1 receptor blockers (antihypertensive drugs) or prostatic hypertrophy therapeutic drugs (e.g., doxazosin mesylate, urapidil, prazosin hydrochloride, bunazosin hydrochloride, oxendolone, progesterone caproate, chlormadinol acetate, tamsulosin hydrochloride, naftopidil, silodosin), 5α-reductase inhibitors (e.g., dutasteride), antiandrogens (e.g., methyltestosterone, testosterone propionate, testosterone enanthate, bicalutamide, enzalutamide), PDE5 inhibitors (e.g., tadalafil, etc.) and crude drugs. Such a second urination-improving drug can be used in a ratio of about 0.1 to 100 parts by mass (for example, about 1 to 50 parts by mass) relative to 100 parts by mass of the 2-oxapregnanol compound represented by the aforementioned formula (1).
[0079] The urination disorder improving agent (or preparation) according to the present invention is effective in treating and / or preventing various urination disorders, and improves or alleviates (or reduces) urination disorders. Therefore, the urination disorder improving agent can also be referred to as a therapeutic agent and / or preventive agent for treating and / or preventing urination disorders, or an alleviator or mitigator for alleviating or reducing urination disorders.
[0080] Examples of urination disorders may include the following diseases or symptoms: such as dysuria (disordered urination), residual urine sensation, decreased urine force, hesitancy, straining, terminal dripping, post-urination urine dripping, urinary incontinence (including urgency, abdominal pressure, mixed, overflow), frequent urination (including increased daytime frequency, nocturia and psychogenic frequent urination), urgency, bladder pain or bladder pain syndrome, pain during urination, bladder atrophy, neurogenic bladder, detrusor overactivity or overactive bladder (including primary, neurogenic, refractory), chronic cystitis, interstitial cystitis, chronic prostatitis, pelvic pain syndrome, underactive bladder, and overactive detrusor with impaired contractile function. Further, the symptom may be selected from at least one symptom of increased residual urine volume, decreased urination efficiency, increased bladder capacity, increased bladder wet weight and increased kidney wet weight. Such at least one symptom may be used as an indicator or standard for urination disorders. Urinary disorders may be obstacles that cause these multiple diseases or symptoms to be compounded. For example, dysuria may also be accompanied by a feeling of residual urine and a weakened urinary force. Dysuria is usually manifested as symptoms including a feeling of residual urine, a weakened urinary force, urinary incontinence, frequent urination or urgency (e.g., lower urinary tract symptoms). Therefore, according to the present invention, urination can be improved or promoted.
[0081] The above-mentioned urination disorder may be accompanied by prostatic hypertrophy or may not be accompanied by prostatic hypertrophy. That is, the urination disorder may be any one of urination disorder not accompanied by benign prostatic hyperplasia and urination disorder accompanied by benign prostatic hyperplasia. Regardless of the degree and / or existence of prostatic hyperplasia, the present invention can effectively treat or improve urination disorder.
[0082] The urination disorder can be a urination disorder associated with smooth muscle contraction disorder (bladder smooth muscle contraction disorder). The type of urination disorder can include, for example, urination disorders associated with the following diseases: diseases that cause or induce neurogenic bladder; diabetes; neuropathy associated with diabetes (afferent or efferent neuropathy of the urination reflex system); hyperglycemia; and neurological diseases associated with hyperglycemia. These urination disorders may be accompanied by benign prostatic hyperplasia, or may not be accompanied by benign prostatic hyperplasia; and there are many cases of urination disorders without benign prostatic hyperplasia. Diseases that cause or induce neurogenic bladder can be, for example, cerebrovascular disorders (stroke), Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebellar degeneration, myelomeningocele (spina bifida), tethered cord syndrome, herniated intervertebral disc, spinal stenosis, and peripheral neuropathy of the bladder caused by rectal cancer or uterine cancer surgery. Specifically, in neurogenic bladder as an example, even without benign prostatic hyperplasia, urination disorder may be caused by inhibition of smooth muscle contraction caused by central or peripheral neuropathy. Moreover, it is well known that in diabetic patients and / or hyperglycemic patients, whether insulin-dependent or insulin-independent, central or peripheral nerves are damaged or injured, and concurrent neuropathy (such as, sensory (afferent) or efferent neuropathy of the urination reflex system) produces urination disorder. Diabetes can be type I and / or type II diabetes. Therefore, urination disorder can be caused by inhibition of bladder smooth muscle contraction inhibition via the aforementioned neuropathy. In addition, clinical and non-clinical known urination disorder (for example, bladder underactivity, diabetic urination disorder) is related to bladder smooth muscle contraction disorder. The present invention can effectively treat or improve such urination disorder without benign prostatic hyperplasia. Therefore, the subject with urination disorder can be any one of male or female (male or female). Compounds according to the present invention or pharmaceutically acceptable salts thereof and urination disorder improvers (or preparations) are used for effectively treating or improving urination disorder regardless of gender.
[0083] The urination disorder improver according to the present invention may include a single 2-oxapregnanol compound represented by formula (1) or a pharmaceutically acceptable salt thereof, or may be used as a pharmaceutical composition or a physiologically active composition comprising a combination of formula (1) or a pharmaceutically acceptable salt thereof and a carrier (e.g., a pharmacologically or physiologically acceptable carrier). The carrier of the urination disorder improver (pharmaceutical composition, physiologically active composition) may be selected according to the form of the preparation (i.e., dosage form), route of administration, application (or use). The dosage form is not particularly limited to a specific one, and may be a solid preparation [e.g., powder preparation, powder, granular preparation (e.g., granular or microgranular preparation, etc.), spherical or spherical preparation, pill, tablet, capsule (e.g., soft capsule or hard capsule, etc.), dry syrup, suppository, film or sheet preparation, etc.], a semisolid preparation (e.g., cream, ointment, gel and gumdrop-like preparation), or a liquid preparation (e.g., injection solution (or injection) and syrup). In a preferred embodiment, the urination disorder improving agent according to the present invention has a dosage form of a solid preparation, particularly granules, tablets or capsules.
[0084] In addition, the aforementioned powder preparations also include sprays, aerosols, etc. Capsules can be any of soft capsules or hard capsules; they can be liquid-filled capsules; or they can be capsules filled with solid preparations (such as granules). Moreover, the preparation can be a freeze-dried preparation. Further, the urination disorder improver (or preparation) according to the present invention can be a preparation with controlled release of the drug (extended release preparation or sustained release preparation or rapid release preparation). In addition, the administration route of the urination disorder improver (or preparation) is not limited to a specific route. The urination disorder improver (or preparation) can be an oral preparation (for example, granules, powders, tablets (for example, sublingual tablets and orally disintegrating tablets), capsules and film preparations, etc.) or parenteral preparations (for example, inhalants, transdermal preparations, nasal preparations, suppositories and injections). Further, the preparation can be a topical preparation (for example, ointments, patches or cataplasms, etc.). The urination disorder improver (or preparation) according to the present invention is a solid preparation (for example, an oral solid preparation). Therefore, the components of the solid preparation will be mainly explained hereinafter.
[0085] For example, depending on the route of administration and the application of the preparation, the carrier can be selected from Japanese Pharmacopoeia 16 thEdition, (1) Handbook of Pharmaceutical Excipients (Maruzen Company, Ltd., (1989)), (2) Japanese Pharmaceutical Excipients Dictionary 2016 (Yakuji Nippo Ltd., issued February, 2016), (3) Pharmaceutics, revised fifth edition (Nankodo, Co., Ltd. (1997)) and (4) Japanese Pharmaceutical Excipients 2003 (Yakuji Nippo Ltd., issued August, 2003) listed in the components (e.g., diluents or excipients, binders, disintegrants, lubricants and coating agents). For example, as a carrier of a solid preparation, at least one carrier selected from a diluent, a binder and a disintegrant is often used. In addition, the urination disorder improving agent (or preparation) may contain lipids.
[0086] Examples of the aforementioned diluents may include sugars or sugar alcohols, such as lactose, glucose, sucrose, mannitol, sorbitol or xylitol; starches, such as corn starch; polysaccharides, such as crystalline cellulose (including microcrystalline cellulose); and silicon dioxide or silicates, such as light anhydrous silicic acid. As examples of binders, soluble starches, such as pregelatinized starch or partially pregelatinized starch, polysaccharides, such as gum arabic (or gum arabic), dextrin or sodium alginate, synthetic polymers, such as polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), carboxyvinyl polymers, polyacrylic acid polymers, polylactic acid or polyethylene glycol, and cellulose ethers, such as methylcellulose (MC), ethylcellulose (EC), carboxymethylcellulose (CMC), sodium carboxymethylcellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC). Examples of disintegrants may include sodium starch glycolate, carboxymethylcellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, cross-linked sodium carboxymethylcellulose, crospovidone and low-substituted hydroxypropylcellulose. These carriers can be used alone or in combination.
[0087] As the aforementioned coating agent, for example, saccharides or sugars, cellulose derivatives such as ethylcellulose or hydroxymethylcellulose, polyoxyethylene glycol, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, methyl methacrylate-(meth)acrylic acid copolymer and eudragit (copolymer of methacrylic acid and acrylic acid) can be used. Such coating agents can be enteric components (e.g., cellulose phthalate, hydroxypropylmethylcellulose phthalate and methyl methacrylate-(meth)acrylic acid copolymer), or gastric components containing polymers containing alkaline components such as dialkylaminoalkyl (meth)acrylates (e.g., eudragit). The preparation can be a capsule having, for example, an enteric component or a gastric component as a capsule shell.
[0088] In the preparation, known additives can be appropriately used according to the route of administration, dosage form, etc. Such additives may include, for example, lubricants, disintegration aids, antioxidants or antioxidants, stabilizers, bactericides or preservatives, fungicides or antibacterial agents, antistatic agents, flavoring agents or masking agents, colorants, deodorants or fragrances, cooling agents and defoamers. These additives may be used alone or in combination.
[0089] The urination disorder improving agent (pharmaceutical composition or preparation) according to the present invention can be prepared by a conventional preparation method (for example, the preparation method described in Japanese Pharmacopoeia 16th edition or a method based on the preparation method) using an active ingredient and additional carrier components and / or optional additives or other components.
[0090] The aforementioned 2-oxapregnane compound or a pharmaceutically acceptable salt thereof, which is a known compound as described above, has been used for many years and has high stability and high safety.
[0091] The urination disorder improver (pharmaceutical composition or preparation) according to the present invention can be safely administered to humans or non-human animals, typically mammals (e.g., humans, mice, rats, rabbits, dogs, cats, cattle, horses, pigs and monkeys). The dosage (dosage or dosage) can be selected according to the category, age, body weight and condition (e.g., performance status, disease state, the presence of complications) of the subject to be administered, duration of administration (or cycle or regimen), dosage form, method of administration (or route), etc. For example, according to the compound represented by formula (1), the dosage (daily dose) for humans can be about 0.01 to 100 mg / day, preferably about 0.05 to 75 mg / day (e.g., about 0.1 to 40 mg / day), and particularly about 0.05 to 10 mg / day (e.g., about 0.1 to 3 mg / day).
[0092] The method of administration (or route) can be oral administration or local parenteral administration (e.g., subcutaneous injection, intramuscular administration, rectal administration and vaginal administration). In a preferred embodiment, the urination disorder improver (pharmaceutical composition or preparation) according to the present invention is orally administered. The frequency of administration is not particularly limited to a specific one, and can be, for example, once a day, or, if necessary, multiple times a day (e.g., twice or three times a day).
[0093] As described above, the present invention also includes a method for treating, improving or alleviating (to reducing) urinary disorders (and a method for improving or promoting urination), the method comprising administering the aforementioned 2-oxopregnanol compound or its pharmaceutically acceptable salt as an active ingredient to a subject suffering from urinary disorders, or administering a urinary disorder improver (pharmaceutical composition or preparation) to a subject suffering from urinary disorders. Further, the present invention includes the use of 2-oxopregnanol compound or its pharmaceutically acceptable salt as an active ingredient for treating or improving or alleviating (or reducing) urinary disorders (and improving or promoting urination), or the use of a urinary disorder improver (pharmaceutical composition or preparation) for treating or improving or alleviating (or reducing) urinary disorders (and improving or promoting urination). The present invention also includes the use of the aforementioned 2-oxopregnanol compound or its pharmaceutically acceptable salt in the preparation of a urinary disorder improver, a urination improver or a urination promoter.
[0094] Example
[0095] The following examples are intended to describe the present invention in more detail and should by no means be construed as defining the scope of the present invention.
[0096] Test Example 1
[0097] The lower urinary tract obstruction model of rats was used as a test system. The test substance was orally administered to the lower urinary tract obstruction model repeatedly for two (2) weeks to examine the effect on the urination function in the lower urinary tract obstruction model.
[0098] In more detail, rats (female, Crl:CD (SD), 8 weeks old; Charles River Laboratories Japan, Inc.) were surgically formed with lower urinary tract obstruction, and the test substance was repeatedly orally administered once a day for two (2) weeks. After the administration was completed, each rat was subjected to bladder catheterization under anesthesia, cystometry was performed without anesthesia, and then cystometry was performed under urethane anesthesia, and euthanasia was performed under deep anesthesia, and rat tissues (bladder, kidney) were removed or surgically removed. As a normal group, rats without surgery to form lower urinary tract obstruction were used.
[0099] The test system, test substances and dosages were as follows.
[0100] Normal group: 0.5v / v% polysorbate 80 solution. 10mL / kg (n=6)
[0101] Solvent group (control group): 0.5 v / v% polysorbate 80 solution, 10 mL / kg (n=15)
[0102] Group A: Compound A, 10 mg / kg (n=15)
[0103] Group B3: Compound B, 3 mg / kg (n=7)
[0104] Group B10: Compound B, 10 mg / kg (n=7)
[0105] The names of Compound A and Compound B are as follows.
[0106] Compound A: 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione
[0107] Compound B: TZP-4238 (17α-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione
[0108] Residual urine volume, voiding efficiency, and bladder capacity were measured as follows.
[0109] [Residual urine volume]
[0110] After urination, residual urine was aspirated from the outlet end of the catheter placed in the bladder to measure the volume (mL) of residual urine.
[0111] [Urination efficiency]
[0112] After urination, the weight of the excreted urine is measured to determine the excretion volume (g = mL), and the urination efficiency is calculated by the following formula:
[0113] Urinary efficiency (%) = [(excretion volume (mL)) / (excretion volume (mL) + residual urine volume (mL))] × 100
[0114] [Bladder capacity]
[0115] The bladder capacity was calculated from the voided volume and residual urine volume by the following formula:
[0116] Bladder capacity (mL) = excretion volume (mL) + residual urine volume (mL)
[0117] Furthermore, the wet weight of the extracted bladder and the wet weight of the extracted kidney were measured.
[0118] Figures 1 to 6 Results are shown for residual urine volume, micturition efficiency, bladder capacity, wet weight of harvested tissues (bladder, kidney), and survival rate in a female rat lower urinary tract obstruction model. Figure 1 Shows the relationship between residual urine volume and test substance. Figure 2 The relationship between urination efficiency and the test substance is shown. Figure 3 Shows the relationship between bladder capacity and test substance. Figure 4 and Figure 5 The relationship between the bladder wet weight and the test substance and the relationship between the kidney wet weight and the test substance are shown separately. Figure 6 The relationship between survival rate and test substance is shown.
[0119] As from Figures 1 to 3 It can be seen that Group B (Group B3 and Group B10) showed a significant increase in residual urine volume and bladder capacity and a decrease in urination efficiency compared with the control group (solvent group). In contrast, Group A showed a significant decrease in residual urine volume and bladder capacity and a significant increase in urination compared with the control group. Figure 4 and Figure 5 Obviously, group A is in the direction of significantly inhibiting the increase in wet weight of bladder and kidney associated with lower urinary tract obstruction, while group B is in the direction of increasing these wet weights. Therefore, group B is in the direction of not improving urination function or worsening it, while group A shows significant improvement in the reduced urination function caused by lower urinary tract obstruction. Further, group A shows that urination function is significantly improved in female rats without prostate in the lower urinary tract obstruction model system. These results show that compound A improves urination disorder regardless of the presence of prostate enlargement.
[0120] Further, as from Figure 6 Obviously, group B showed a decreased survival rate of rats with lower urinary tract obstruction, whereas group A showed no decreased survival rate. The results confirmed that compound A has high safety.
[0121] Although these test substances belong to the same 2-oxapregnanolone compound (progesterone), it is not clear why the above results were obtained in female rats. One possible reason may be as follows.
[0122] In clinical practice, it is believed that increased progesterone during pregnancy relaxes the periuterine organs including the bladder. It has been reported that for rats, pregnancy and progesterone affect bladder muscarinic receptors to increase bladder capacity or inhibit bladder contraction (Pharmacology. 50 (3): 192-200. 1995). In addition to the relaxation caused by progesterone, the bladder is functionally hypotonic due to mechanical compression from behind the pregnant uterus. Therefore, progesterone may induce the development or phenomenon of residual urine or vesicoureteral reflux.
[0123] Group B exhibits a strong progesterone-like effect and is considered or expected to inhibit bladder contraction by the above mechanism. In a pathological model in which bladder function is strongly impaired, such as a female lower urinary tract obstruction model, for Group B, it is possible that compound B excessively inhibits bladder contraction, causing pathological aggravation or regression.
[0124] On the other hand, compound A has a mild anti-progesterone effect. Female rats have an estrous cycle of about four (4) days. For group A, it is possible that compound A antagonizes endogenous progesterone that increases according to the estrous cycle to produce a protective effect against further inhibition of bladder function in the lower urinary tract obstruction model.
[0125] Test Example 2
[0126] The lower urinary tract obstruction model of rats was used as a test system. The test substance was repeatedly orally administered to the lower urinary tract obstruction model for 14 days to examine the effect on urination function in the lower urinary tract obstruction model. The lower urinary tract obstruction model is not a benign prostatic hyperplasia model with prostatic hypertrophy.
[0127] In more detail, rats (male, Crl:CD (SD), 8 weeks old; Charles River Laboratories Japan, Inc.) were surgically formed with lower urinary tract obstruction, and the test substance was repeatedly orally administered once a day for 14 days. After the administration was completed, bladder catheterization was performed on each rat under anesthesia, and cystometry was performed without anesthesia, and residual urine volume and urination efficiency were evaluated.
[0128] The test substances and the dosages in the test system (male rats with lower urinary tract obstruction) were as follows.
[0129] Solvent group (control group): 0.5 v / v% polysorbate 80 solution, 10 mL / kg (n=8)
[0130] Group A: Compound A, 10 mg / kg (n=12)
[0131] Group C: Compound C (dutasteride), 0.5 mg / kg (n=11)
[0132] Dutasteride is a 5-alpha reductase inhibitor.
[0133] The results are shown in Figure 7 and Figure 8 middle.
[0134] Figure 7 and Figure 8 The results showed that in the male rat lower urinary tract obstruction model, group A had a stronger improvement effect on urination function (residual urine volume, urination efficiency) compared with group C (dutasteride).
[0135] Test Example 3
[0136] Old male rats (22 weeks old; Charles River Laboratories Japan, Inc.) were examined, and the relationship between the test substance and the contractile response of the bladder and urethra was evaluated. Since the rats are old, the rats are a model in which prostatic hypertrophy is expected.
[0137] The test substance was orally administered to high-aged rats repeatedly once a day for two (2) weeks, and then bladder samples were removed from each rat. The bladder samples were suspended at a resting tension of about 9.8 mN in a thermostatic Magnus tube (37° C.) filled with physiological saline solution, ventilated with 95% O2-5% CO2 gas, and subjected to isometric contraction tests using rectangular wave electric field stimulation (EFS, amplitude; 0.3 ms, frequency; 1, 2, 5, 10, 20 Hz, duration; 5 s) or carbachol (CCH, 100 nmol / L to 100 μmol / L) and KCl (40, 80 mmol / L).
[0138] The test substances and dosages in the test system (old-age male rats) were as follows.
[0139] Solvent group (control group): 0.5 v / v% polysorbate 80 solution, 10 mL / kg (n=6)
[0140] Group A: Compound A, 10 mg / kg (n=6)
[0141] Group C: Compound C (dutasteride), 0.3 mg / kg (n=6)
[0142] The results are shown in Fig. 9 and Fig.10 middle.
[0143] Fig. 9 and Fig.10 Compared with group C, in group A, the bladder efferent nerve stimulation or carbachol (muscarinic receptor stimulation) and KCl (depolarization-dependent Ca 2+ The bladder contraction tension caused by stimulation is significantly strong or has strong directionality.
[0144] Test Example 4
[0145] As described below, as a urination disorder model, a urination disorder model associated with diabetes was prepared to evaluate urination disorder. This model does not have benign prostatic hyperplasia and is a urination disorder model associated with neuropathy and smooth muscle contraction disorder.
[0146] The body weight of rats (male, Crl:CD (SD), 5 weeks old; Charles River Laboratories Japan, Inc.) was measured. After the rats were fasted overnight, blood was collected from the tail vein to measure fasting blood glucose. Based on body weight and fasting blood glucose levels, the rats were divided into two (2) groups by random, multivariate block allocation. On the second day after the rats were grouped, the first group received intraperitoneal administration of citrate buffer (pH 4.5) (10 mL / kg) with a concentration of 0.1 mmol / L, and the second group received intraperitoneal administration of streptozotocin (STZ; Sigma-Aldrich) (50 mg / kg). Streptozotocin (STZ) was administered in the form of a streptozotocin solution with a concentration of 5 mg / mL in citrate buffer.
[0147] About 1 week after administration of streptozotocin (STZ), body weight and fasting blood glucose were measured. In the streptozotocin (STZ) administration group (the second group), individuals with fasting blood glucose levels not less than 300 mg / dL were used as animals with induced diabetes. These animals with induced diabetes are models without prostate abnormalities (without benign prostatic hyperplasia). Based on body weight and fasting blood glucose levels, the animals (models) with induced diabetes were divided into three (3) groups by random, multivariate block allocation.
[0148] To three model groups with induced diabetes, 0.5v / v% polysorbate 80 solution (0.5%P) (10mL / kg), compound A (3mg / kg) and compound A (10mg / kg) were orally administered, respectively, wherein the dosage regimen in all groups was once a day, only on weekdays, for four (4) weeks. Moreover, for the above-mentioned first group, 0.5v / v% polysorbate 80 solution (0.5%P) (10mL / kg) (normal group) was orally administered with the same dosage regimen. In the last day of administration, the cannula was inserted and fixed to the top of the bladder under isoflurane anesthesia, and cystometrometry (Cystometogram, CMG) was performed successively under awake conditions and under urethane anesthesia to measure bladder pressure, excretion and residual urine volume. After the measurement was completed, blood was collected under deep isoflurane anesthesia, and then the prostate (ventral prostate, dorsolateral prostate), seminal vesicle, bladder and kidney were removed, and each was weighed. Moreover, the blood glucose level in the collected blood was determined.
[0149] The test substances and the dosages in the test system (rats with diabetes-related urination disorders) were as follows.
[0150] Normal group: citrate buffer 10 mL / kg (intraperitoneal administration), 0.5% P 10 mL / kg (oral administration) (n=10)
[0151] Solvent group (control group): STZ 50 mg / kg (intraperitoneal administration), 0.5% P 10 ml / kg (oral administration) (n=10)
[0152] Group A3: STZ 50 mg / kg (intraperitoneal administration), compound A 3 mg / kg (oral administration) (n=10)
[0153] Group A10: STZ 50 mg / kg (intraperitoneal administration), compound A 10 mg / kg (oral administration) (n=9)
[0154] Urinary parameters:
[0155] The obtained data of intravesical pressure, voiding volume and residual urine volume were analyzed, and bladder capacity (mL), residual urine volume (mL) and urination efficiency (%) were determined as urination parameters in each urination. Regarding these urination parameters, the average of two measurements was calculated and used as the measured value for each individual.
[0156] Tissue Weight:
[0157] From the weight of ventral prostate and dorsolateral prostate, calculate the weight of whole prostate.The respective weight of prostate, seminal vesicle, bladder and kidney is converted into the tissue weight of every 100g body weight.For A3 group and A10 group of administration compound A, calculate the inhibition rate (one decimal place) of the respective weight of prostate and seminal vesicle relative to the respective weight of prostate and seminal vesicle in solvent group.
[0158] In statistical analysis, for each group, calculate the mean value and standard deviation of final body weight, tissue weight (prostate, seminal vesicle, bladder and kidney) of every 100g body weight, blood sugar level and various urination parameters.For statistical analysis, carry out significant difference test with SAS statistical analysis system (SAS9.4 version, SAS Institute Japan Ltd. manufactures).Between normal group and solvent group, carry out bilateral student t test, and judge that the significance level (critical rate) lower than 5% has statistically significant difference.In addition, between solvent group and A3 group and between solvent group and A10 group, carry out Williams's multiple comparison test (Williams's multiple comparison test), judge that the significance level (critical rate) lower than 2.5% has statistically significant difference.
[0159] Asterisk "*" indicates 5% significance (P<0.05 (vs. normal group) (Student's t test)), and hash mark "#" indicates 2.5% significance (P<0.025 (vs. solvent group) (Williams' multiple comparison test)).
[0160] Bladder contractility by nomogram analysis:
[0161] In cystometrometry (CMG) under anesthesia, the maximum urine flow rate (mL / second) and the bladder pressure at maximum urine flow (cmH2O) were determined to evaluate the bladder contraction force during urination in each group. In particular, for each group, the average values of the maximum urine flow rate Qmax (mL / second), the bladder pressure at maximum urine flow PdetQmax (cmH2O) and the bladder capacity BC (mL) were calculated, and the maximum urine flow rate / bladder capacity on the Y axis was plotted against the bladder pressure at maximum urine flow / bladder capacity on the X axis. It was judged that the shorter the distance from the origin, the weaker the bladder contraction force, and the farther the distance from the origin, the stronger the bladder contraction force.
[0162] The results are shown in Table 1. Figures 11 to 13 (cystometry (CMG) data under awake conditions), Figure 14 to Figure 16 (cystometrometry (CMG) data under anesthesia) and Fig.17 (Nomogram Analysis Results). In each column of the table, "mean ± standard deviation" is listed.
[0163] [Table 1]
[0164]
[0165] [Weight, tissue weight, and blood glucose levels]
[0166] Compared with the normal group, the vehicle group (control group) showed a significant decrease in body weight, and a significant increase in bladder and kidney weights. In addition, blood sugar levels also increased significantly. In contrast, the A3 group and the A10 group showed a significant decrease in prostate and seminal vesicle weights, and had no effect or influence on body weight, blood sugar levels, bladder and kidney weights.
[0167] As is apparent from the blood glucose levels of the A3 and A10 groups relative to the vehicle group, no therapeutic effect on diabetes was found in Compound A. In addition, the model with induced diabetes developed urination disorder without prostatic hypertrophy.
[0168] [Cystomenometric measurement (CMG): bladder capacity, residual urine volume and urination efficiency]
[0169] Figures 11 to 13 The results of the analysis of the cystometrometry (CMG) measurement data under awake conditions are shown. Compared with the normal group, the vehicle group (control group) showed a significant increase in bladder capacity and residual urine volume, and a significant decrease in urination efficiency. Compared with the vehicle group (control group), the A3 group showed a significant decrease in bladder capacity and residual urine volume, and an increase in urination efficiency. The A10 group also showed a significant decrease in bladder capacity and residual urine volume, and a significant increase in urination efficiency (P = 0.0359, Williams' multiple comparison test).
[0170] Figures 14 to 16 The results of the analysis of the cystometrometry (CMG) measurement data under anesthesia are shown. Compared with the normal group, the solvent group (control group) showed a significant increase in bladder capacity and residual urine volume, and a significant decrease in urination efficiency. Compared with the solvent group (control group), the A3 group showed a significant decrease in residual urine volume. The A10 group also showed a significant decrease in residual urine volume and a decrease in bladder capacity (P = 0.0336, Williams' multiple comparison test). Moreover, the A3 group and the A10 group showed an improvement in urination efficiency.
[0171] In addition, in the nomogram analysis ( Fig.17 ), it was judged that the A3 group and the A10 group, each of which had a greater distance from the origin than the solvent group (control group), had a stronger bladder contraction force during urination.
[0172] Therefore, compound A showed no therapeutic effect on diabetes (group A3 and group A10), and further significantly improved urination disorder in the model of induced diabetes without prostatic hypertrophy.
[0173] Test Example 5
[0174] Compound A and Compound D (mifepristone) were tested for their antiprogesterone activity. Specifically, sex hormones and test substances were repeatedly administered to ovariectomized rats as a test system, and the antiprogesterone effect (antiprogesterone activity) was measured using the fluctuation of uterine weight associated with decidual tumor formation in rats (relative to the inhibitory effect on body weight gain) as an index.
[0175] In more detail, rats (female, Crl:CD (SD), 5 weeks old: Charles River Laboratories Japan) were ovariectomized, and high-dose estrone of 5 μg / animal was subcutaneously administered to the rats once a day for 3 days starting from 1 week after ovariectomy. From the second day after a one-day rest period, the rats received subcutaneous injection of low-dose estrone (1 μg / animal), intramuscular administration of progesterone (6 mg / kg) and oral administration of the test substance once a day for eight (8) days. In the middle of the administration, on the 4th day after the start of administration, the rats were subjected to stimulation treatment of the right uterine decidualization reaction. On the second day after the last administration, the uterine weight (right uterine body) was measured (n=6). Group E was subjected to ovariectomy and stimulation treatment of the decidualization reaction, but no hormone treatment was performed.
[0176] The test substances and the dosages in the test system (ovariectomized rats) are as follows.
[0177] Group E: Ovariectomized rats without hormone treatment
[0178] 0.5v / v% polysorbate 80 solution, 10mL / kg (n=6)
[0179] Solvent group (control group): 0.5 v / v% polysorbate 80 solution, 10 mL / kg (n=6)
[0180] Group A3: Compound A, 3 mg / kg (n=6)
[0181] Group A10: Compound A, 10 mg / kg (n=6)
[0182] Group A30: Compound A, 30 mg / kg (n=6)
[0183] Group D: Compound D (mifepristone), 3 mg / kg (n=6)
[0184] The results are shown in Fig.18 middle.
[0185] like Fig.18 As shown, compared with the solvent group, group D showed a significant inhibitory effect (inhibition rate: 89.5%). Compared with the solvent group, although group A3 did not show a significant inhibitory effect (inhibition rate: 15.0%), groups A10 and A30 showed significant inhibitory effects (inhibition rates: 63.0% and 83.3%, respectively). The results show that compound A has anti-progesterone activity.
[0186] Test Example 6
[0187] As described below, a urination disorder model associated with streptozotocin-induced diabetes was prepared as a urination disorder model according to Test Example 4 to evaluate the effects of Compound A and Compound C on urination disorder. This model does not have benign prostatic hyperplasia and is a model of urination disorder associated with neuropathy and smooth muscle contraction disorder.
[0188] The body weight of rats (male, Crl:CD (SD), 5 weeks old; Charles River Laboratories Japan, Inc.) was measured. Based on body weight, the rats were divided into two (2) groups. On the second day after the rats were grouped, the first group received intraperitoneal administration of citrate buffer (pH 4.5) (10 mL / kg) with a concentration of 0.1 mmol / L, and the second group received intraperitoneal administration of streptozotocin (STZ; Sigma-Aldrich) (50 mg / kg). Streptozotocin (STZ) was administered in the form of a streptozotocin solution with a concentration of 5 mg / mL in citrate buffer.
[0189] About 1 week after streptozotocin (STZ) administration, body weight and fasting blood glucose were measured. In the streptozotocin (STZ) administration group (the second group), individuals with fasting blood glucose levels not less than 300 mg / dL were used as animals suffering from induced diabetes. These animals with induced diabetes are models without prostate abnormalities (without benign prostatic hyperplasia). Based on body weight and fasting blood glucose levels, by random, multivariate block allocation, animals (models) with induced diabetes were grouped into three (3) groups.
[0190] To three model groups with induced diabetes, 0.5v / v% polysorbate 80 solution (0.5%P) (10mL / kg), compound C (3mg / kg) and compound C (dutasteride) (0.3mg / kg) were orally administered, respectively, wherein the dosage regimen in all groups was once a day, only on weekdays, for four (4) weeks. In addition, to the above-mentioned first group, 0.5v / v% polysorbate 80 solution (0.5%P) (10mL / kg) (normal group) was orally administered with the same dosage regimen. On the last day of administration, the cannula was inserted and fixed to the top of the bladder under isoflurane anesthesia, and cystometrometry (Cystometogram, CMG) was performed successively under awake conditions and under urethane anesthesia to measure bladder pressure, excretion and residual urine volume. After the measurement was completed, blood was collected under deep isoflurane anesthesia, and then the prostate (ventral prostate, dorsolateral prostate) was removed and weighed separately. In addition, the blood glucose level in the collected blood was determined.
[0191] The test substances and the dosages in the test system (rats with diabetes-related urination disorders) were as follows.
[0192] Normal group: citrate buffer 10 ml / kg (intraperitoneal administration), 0.5% P 10 mL / kg (oral administration) (n=10)
[0193] Solvent group (control group): STZ 50 ml / kg (intraperitoneal administration), 0.5% P 10 mL / kg (oral administration) (n=10)
[0194] Group A3: STZ 50 mg / kg (intraperitoneal administration), compound A 3 mg / kg (oral administration) (n=10)
[0195] Group C0.3: STZ 50 mg / kg (intraperitoneal administration), Compound C (dutasteride) 0.3 mg / kg (oral administration) (n=10)
[0196] Urinary parameters: The residual urine volume (mL) and urination efficiency (%) in each urination were measured as urination parameters in the same manner as in Test Example 4, and the average of two measurements was taken as the measured value for each individual.
[0197] Prostate weight: The weight of the prostate (ventral prostate, dorsolateral prostate and whole) was converted to tissue weight per 100 g body weight in the same manner as in Test Example 4. For the A3 group administered with Compound A and the C0.3 group administered with Compound C, the inhibition rate (one decimal place) of the prostate weight relative to the prostate weight in the solvent group was calculated.
[0198] In the statistical analysis, the significant difference test was performed in the same manner as in Experimental Example 4. A two-sided Student's t test was performed between the normal group and the solvent group to determine that the significance level (critical rate) below 5% had a statistically significant difference, wherein the asterisk "*" indicated a significance of 5%. In addition, Dunnett's multiple comparison test was performed between the solvent group and the A3 group and between the solvent group and the C0.3 group to determine that the significance level (critical rate) below 5% had a statistically significant difference, wherein the pound sign "#" indicated a significance of 5%.
[0199] Bladder contraction force by nomogram analysis: The bladder contraction force of each group during urination was evaluated in the same manner as in Test Example 4. The maximum urine flow rate / bladder capacity on the Y axis was plotted against the bladder pressure at maximum urine flow / bladder capacity on the X axis. It was determined that the shorter the distance from the origin, the weaker the bladder contraction force, and the farther the distance from the origin, the stronger the bladder contraction force.
[0200] The results are shown in Table 2. Fig.19 and 20 (cystometrometry (CMG) data under awake conditions) and Fig.21 (Nomogram analysis results).
[0201] [Table 2]
[0202]
[0203] [Prostate weight and blood sugar levels]
[0204] Compared with the solvent group, the weight of the ventral prostate, the dorsolateral prostate and the whole prostate was significantly atrophied in the A3 group and the C0.3 group, with the same level (P < 0.05). The comparison of the normal group and the solvent group showed that there was no significant difference in the weight of the prostate, thus confirming that the model with induced diabetes is a model without prostatic hypertrophy. For such a diabetic model, since the A3 group and the C0.3 group did not statistically affect the blood sugar level of the solvent group as in the above-mentioned Test Example 4, it was confirmed that Compound A and Compound C did not show a therapeutic effect on diabetes.
[0205] [Cystomenometric measurement (CMG): residual urine volume and urination efficiency]
[0206] The results of the analysis of the data measured by cystometry (CMG) under awake conditions, such as Fig.19 and Fig. 20 As shown, the solvent group accompanied by STZ treatment (induced diabetes) significantly increased residual urine volume and significantly reduced urination efficiency compared with the normal group (p < 0.05). According to these results, the model with induced diabetes develops urination disorders. At the same time, compared with the solvent group, the A3 group showed a significant decrease in residual urine volume (p < 0.05), although the C0.3 group did not statistically affect the residual urine volume compared with the solvent group. Moreover, compared with the solvent group, the A3 group showed a significant increase in urination efficiency (p < 0.05), while compared with the solvent group, the C0.3 group showed that it did not statistically affect the urination efficiency. In terms of urination efficiency, it was confirmed that there was a trend showing a statistical difference between group A3 and group C0.3 (p = 0.0757, Student's t test).
[0207] In the nomogram analysis ( Fig.21 ), the normal group showed the farthest distance from the origin, and group C0.3 and the solvent group were in almost the same position. In contrast, group A3 showed a farther distance from the origin than the solvent group. From these results, it can be judged that group A3 has a stronger bladder contraction force during urination than the solvent group and group C0.3.
[0208] Therefore, Compound A showed no therapeutic effect on diabetes (Group A3), and further significantly improved urination disorder in the model of induced diabetes without prostatic hypertrophy.
[0209] Industrial Applicability
[0210] The urination disorder improving agent according to the present invention can effectively improve urination disorder, such as residual urine feeling, slow urine flow, urinary incontinence or frequent urination, because it contains the 2-oxapregnanolone compound represented by formula (1). Therefore, the quality of life of people (especially the elderly) suffering from urination disorder can be improved and enhanced.
Claims
1. Use of a 2-oxapregnanol compound or a pharmaceutically acceptable salt thereof in the preparation of a urination disorder improving agent for improving urination disorder or symptoms without benign prostatic hyperplasia, wherein the urination disorder or symptom is selected from at least one of increased residual urine volume, decreased urination efficiency, increased bladder capacity, increased bladder wet weight and kidney wet weight, and decreased bladder contraction strength, wherein the 2-oxapregnanol compound is 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnene-3,20-dione.
2. Use of a 2-oxapregnanolone compound or a pharmaceutically acceptable salt thereof in the preparation of a urination disorder improving agent for improving urination disorder or symptoms without benign prostatic hyperplasia, wherein the urination disorder or symptom is selected from at least one of the following: a sense of residual urine, a weakened urinary momentum, hesitant urination, strained urination, terminal dripping, urine dripping after urination, urinary incontinence, frequent urination, urgency, bladder pain or bladder pain syndrome, pain during urination, bladder atrophy, neurogenic bladder, detrusor overactivity or overactive bladder, chronic cystitis, interstitial cystitis, chronic prostatitis, pelvic pain syndrome, underactive bladder, and detrusor overactivity with impaired contractile function, wherein the 2-oxapregnanolone compound is 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione.
3. The use according to claim 1 or 2, wherein the urination disorder is a urination disorder associated with smooth muscle contraction disorder.
4. The use according to claim 1 or 2, wherein the urination disorder is a urination disorder associated with at least one disease selected from the group consisting of: a disease causing neurogenic bladder; diabetes; and neuropathy associated with diabetes.
5. The use according to claim 1 or 2, wherein the urination disorder improving agent improves or promotes urination.
6. The use according to claim 1 or 2, wherein the urination disorder improving agent is administered in an amount of 0.01 to 100 mg / day as 17α-acetoxy-6-chloro-15β-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione.
7. The use according to claim 1 or 2, wherein the urination disorder improving agent is a solid preparation, a semisolid preparation or a liquid preparation.
8. The use according to claim 1 or 2, wherein the urination disorder improving agent is an oral administration preparation or a parenteral administration preparation.
9. The use according to claim 1 or 2, wherein the urination disorder improving agent is a tablet.
Citation Information
Patent Citations
Urinary disturbance improvement agent containing serenoa repens
JP2011020972A
Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity
WO2012020749A1
Therapeutic agent for urinary excretion disorder
CN101663034A
Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
CN102481294A
Novel 2-oxapregnane compound
JP1989199993A
